Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xanthium strumarium pollen is an allergenic extract derived from the pollen of the Xanthium strumarium plant, commonly known as cocklebur. [1] It is used as a diagnostic agent for allergy testing to identify individuals with hypersensitivity to this specific pollen. [1, 5] The extract is administered via skin prick tests or used in in-vitro IgE blood tests to confirm an allergy. [1, 2] Upon administration to a sensitized individual, the allergenic proteins in the pollen extract bind to IgE antibodies on mast cells, triggering the release of histamine and other mediators, which results in a visible wheal and flare reaction, indicating an allergy. [13] Identified allergenic components include Xan Ib (a 103,000 dalton protein) and Xan VIa (a 17,000 dalton glycoprotein). [3] The product is also used for allergen immunotherapy, where repeated administration of the extract can help the body build tolerance and reduce allergic symptoms over time. [1, 8, 9] Manufacturers like Hollister-Stier Laboratories produce this extract in various concentrations for diagnostic and therapeutic use. [15, 18, 24]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xanthium strumarium pollen.